



Targeted and Systemic Immuno-Nanotherapy for Oncology

Combination Therapy with Nanobomb
Plus Platform

DISCLAIMER



This document, including the Financial Model where provided, is provided for general information purposes only and does not take into account each person's individual circumstances. Accordingly, no person should rely or act on the contents of this document, without first obtaining advice from a qualified professional person. For the avoidance of doubt, this document, its author nor Nanotherapy Plus Pty Ltd and its associates, its related bodies corporate and their respective officers and employees should not be regarded as providing investment advice. This document is supplied on the terms and understanding that:



1. Nanotherapy Plus Pty Ltd, and their associates, their related bodies corporate and their respective officers and employees, are not responsible for the results of any actions taken or not taken on the basis of the information in this document;



2. Nanotherapy Plus Pty Ltd does not warrant the accuracy, reliability or completeness of such information and (subject to any statutory liability which cannot be excluded) accepts no responsibility for any errors or omissions from this document (including by negligence).



3. To the maximum extent permitted by law, Nanotherapy Plus Pty Ltd expressly disclaims all and any liability and responsibility to any person, in respect of anything, and for the consequences of anything, done or omitted to be done by any such person, whether wholly or partly, as a result of the contents (whether in whole or in part) of this document.



CONFIDENTIALITY AGREEMENT

- By accepting this document and related information, other than information already published in the public domain, the Receiving Party agrees that all communications or data, in any form, which is disclosed in this document by the Disclosing Party to the Receiving Party, is protected here under against unrestricted disclosure or competitive use by the Receiving Party and shall be deemed to be "Confidential Information".
- The Receiving Party shall safeguard all Confidential Information for a period of three years from the date of disclosure unless earlier waived in writing by the Disclosing Party.
- The Receiving Party shall use all reasonable safeguards against the unauthorized disclosure of Confidential Information and shall ensure that all of its employees and professional advisers having access to Confidential Information adhere to the terms of this undertaking as if they were a party hereto.
- No license under any trademark, patent, copyright or any other intellectual property right, is granted or implied by the disclosure of any Confidential Information.
- This Agreement shall be governed by and construed in accordance with the laws of the State of Victoria, Australia and the parties agree to submit to the non-exclusive jurisdiction of the Courts of Australia.

Our Vision: Nanobomb Plus

Imagine a world where cancer no longer means fear, suffering, or death.

With **Nanobomb Plus**, we envision a future where tumors are shattered precisely at the source, without harming healthy tissues or debilitating side effects while at the same time our combination therapy will activate natural immunity pathways to provide systemic therapy to destroy metastatic cancers. An unmet clinical need.

This is **Innovation through Transformation** in how we fight cancer. Together, we can make it happen — for millions of patients, for future generations, for humanity.

The time is now. The technology is ready. The impact is global.

Competitive Advantages of Nanotherapy Plus

Clinical & Therapeutic Superiority

- The next decade will see a sharp rise in cancer cases and deaths. The \$ 500B+ oncology market demands scalable, effective solutions now!
- Go-AI, incorporating Nanotherapy Plus, has discovered a combination therapy delivered by Nanobomb Plus **without the use of “Chemotherapy”**.
- The “special protein”, along with checkpoint Inhibitors, creates an immunostimulatory microenvironment for targeted and localized cancer cell killing, while also providing systemic protection. **A clear breakthrough in Precision Oncology + Systemic Oncology.**
- **Market Leadership:** With the cancer therapeutics market projected to hit **\$232 billion by 2026**, "chemo-free" solutions capture the highest-value segment in Precision Oncology. **Nanotherapy Plus is poised to make an impact.**

Competitive Advantages of Nanobomb Plus



Precision Targeting: ⚡ Unlike the "scatter-gun" approach of chemo, our combination therapy works efficaciously to activate the pathways of natural immunity to identify and destroy only cancer cells.

Overcoming Resistance: Many tumors develop "chemo-resistance." Nanobomb Plus, a non-toxic therapy, overcomes resistance through an immunostimulatory environment that leads to "systemic memory".

Combination therapy without chemotherapy drugs: While conventional cancer therapy will continue to use chemotherapy drugs as one of the primary treatments, our non-toxic Nanobomb Plus combination therapy does not include the use of chemotherapy drugs.

Eliminating toxicity: Our primary strategy is to improve the delivery and presentation of biologics with Nanobomb Plus delivered directly to the tumor site, which delivery route also serves to eliminate toxicity if delivered by any other routes.

Immune Memory: Nanobomb Plus "trains" the immune system to remember the cancer (a systemic primer: acts as an in situ vaccine), providing long-term systemic protection and significantly reducing the risk of recurrence.

Higher Success Rates: ✓ Targeted therapies have shown success rates as high as **80%** in specific cases, compared to the traditional **30%** average for systemic chemotherapy. This is a clear advantage of Nanobomb Plus without the debilitating effects of Chemotherapy. **Better Quality of Life for Patients!**

PATENT PENDING:

Our significant discovery, backed by
strong science, leads to compelling IP in
Targeted and Systemic Oncology.

